More than 150 people from around the world gathered virtually this past February for a panel discussion about how to move the needle on gender equity for women in science.

Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target

Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call
Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT

Simulations Plus to Present at Sidoti March Small-Cap Conference
Simulations Plus to Present at Sidoti March Small-Cap Conference

Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
Promising intellectual property resulting from the collaboration with Polish Academy of Sciences will be jointly owned for further development opportunities

Lixoft Adds New Data Formatting and Reporting Modules to MonolixSuite(TM) in Version 2023R1
Update includes enhanced PKanalix, Monolix, and Simulx modules

Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference
We announced that management will be presenting at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually from March 13-15, 2023.

Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference
Management will be presenting at the Raymond James & Associates’ 44th Annual Institutional Investors Conference, scheduled for March 5-8, 2023, at the JW Marriott Grande Lakes in Orlando, Florida.

Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models
Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety

Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool
NAFLDsym v2B Beta represents the first release in the faster, sleeker Julia infrastructure

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
DSX is faster, more user-friendly, and scalable for high-performance computing

Simulations Plus Executes $20 Million Accelerated Share Repurchase Agreement
Initiates first steps in updated capital allocation strategy

Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
Total revenue of $12 million; Diluted Earnings Per Share (EPS) of $0.06; Both in line with fiscal 2023 guidance and Q1 expectations for revenue seasonality shift.
Provides capital allocation strategy update focusing on corporate development activities, $50 million share repurchase program, and internal investment

Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call
Conference call to be on Wednesday, January 4, 2023, at 5 p.m. EST

Simulations Plus and the University of Bath Awarded New FDA Grant
Project will focus on the development of a modeling & simulation framework to support an assessment of bioequivalence for locally-acting drugs in the gastrointestinal tract

Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship
Ex-Anvisa General Manager will contribute to global regulatory strategies involving pharmacometrics

Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who Code
International organization’s mission is to close the gender gap in technology

Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled Products
Collaboration combines novel in vitro experimental methods and mechanistic modeling to accelerate development of orally inhaled drug products (OIDPs) and propose alternative approaches for bioequivalence

Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results
Fiscal 2022 revenue increased 16% year-over-year to $53.9 million
Diluted earnings per share increased 28% year-over-year to $0.60
Provides Fiscal 2023 guidance for total revenue of $59.3 million to $62.0 million (+10% to 15%)

Simulations Plus Announces Cash Dividend
Board of Directors announces quarterly dividend of $0.06 per share